Marked for death: targeting epigenetic changes in cancer. Read more about Marked for death: targeting epigenetic changes in cancer.
Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. Read more about Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine.
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Read more about Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design.
Tackling reproducibility in academic preclinical drug discovery. Read more about Tackling reproducibility in academic preclinical drug discovery.
SLC transporters as therapeutic targets: emerging opportunities. Read more about SLC transporters as therapeutic targets: emerging opportunities.
Bringing together the academic drug discovery community. Read more about Bringing together the academic drug discovery community.
Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Read more about Tankyrase-targeted therapeutics: expanding opportunities in the PARP family.
Targeting the TGFβ signalling pathway in disease. Read more about Targeting the TGFβ signalling pathway in disease.
Membrane transporters in drug development. Read more about Membrane transporters in drug development.
